🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ADRX-070 has received fast track status for use in squamous cell cervical cancer. Read more below. #oncology #nurse #nursing #womenshealth hubs.li/Q03mdLW60

🧠 A phase 2b trial investigating a cancer vaccine in glioblastoma has been cleared to continue as planned. Read more below. #braincancer #oncology #nursing #research hubs.li/Q03msfrq0

🚨BREAKING: The FDA has approved belzutifan for use in adult and pediatric patients 12 or older with pheochromocytoma or paraganglioma. Read more below. #HNCsm #oncology #nurse #nursing hubs.li/Q03mz74w0

🚨BREAKING: Telisotuzumab vedotin-tllv has received accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression. Read more below. #lungcancer #oncology #FDAnews #nurse #nursing hubs.li/Q03mCm-Q0

The combination of bevacizumab and capecitabine yielded promising safety and efficacy data in older patients with mCRC. Read more below. #mCRC #CRCsm #oncology #nurse #nursing hubs.li/Q03mLS9q0

🚨 BREAKING: The FDA has approved retifanlimab both as a monotherapy and in combination with chemotherapy for use in advanced squamous cell carcinoma of the anal canal. Read more below. #analcancer #cancernews #oncology #nurse #FDA #nursing hubs.li/Q03mRJ1T0

The combination of ibrutinib and nivolumab showed efficacy and tolerability in patients with relapsed/refractory CNS lymphoma. Read more below. #oncology #lymphoma #nurse #nursing hubs.li/Q03mX9g90

A nurse practitioner at UCSF Health explained some of the factors that should be considered when selecting a frontline CDK4/6 inhibitor for HR+ breast cancer. Read more below. #BCsm #oncology #nursing hubs.li/Q03m-vNP0

Disitamab vedotin plus toripalimab increased PFS and OS in the first line of therapy for patients with HER2-positive metastatic urothelial cancer. Read more below. #bladdercancer #urothelialcancer #oncology #nurse hubs.li/Q03mXvVd0

Ribociclib plus endocrine therapy produced similar pCR rates to standard chemotherapy in HR-positive, HER2-negative breast cancer. Read more below. #BCsm #breastcancer #oncology #nurse hubs.li/Q03n0lQB0

Telisotuzumab vedotin plus osimertinib showed safety and efficacy in patients with NSCLC and high c-Met overexpression. Read more below. #NSCLC #lungcancer #oncology #nursing hubs.li/Q03n0gHZ0

CAR T-cell therapy CT0596 showed early efficacy and safety signs in patients with relapsed/refractory multiple myeloma. Read more below. #MMsm #myeloma #hematology #oncology #nurse hubs.li/Q03mYQVM0

🎥 Samantha Shenoy, MSN, NP, worked with providers at her institution and beyond to compile best practices on AE management for patients with multiple myeloma on talquetamab. #oncology #nurse #myeloma #interdisciplinarycare hubs.li/Q03n0pCq0

Pembrolizumab plus paclitaxel with or without bevacizumab improvied PFS in platinum-resistant ovarian cancer. Read more below. #ovariancancer #gyncSM #womenshealth #oncology #nurse hubs.li/Q03n0wYz0

Selecting the right treatment path for a patient with ESR1-mutated in metastatic breast cancer can help build trust, according to Kimberly Podsada, BSN, RN, MSN, NP-C, CNS. Read more below. #mBC #BCsm #oncology #breastcancer #advancedpractice hubs.li/Q03n66HQ0

The addition of panitumumab to neoadjuvant chemo improved outcomes for patients with locally advanced colon cancer. Read more below. #coloncancer #GIcancer #oncology #nurse hubs.li/Q03n0Ccf0

Durvalumab plus BCG induction/maintenance improved DFS vs BCG alone in NMIBC. Read more below. #oncology #bladdercancer #news #nursing hubs.li/Q03n0DHM0

ODAC Votes Against Talazoparib Combo for Patients With non-HRR mCRPC. Read more below: hubs.li/Q03nXd9P0